BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 16036037)

  • 1. Levosimendan: a calcium-sensitizing agent for the treatment of patients with decompensated heart failure.
    Lehtonen L
    Curr Heart Fail Rep; 2004 Sep; 1(3):136-44. PubMed ID: 16036037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failure.
    Lehtonen L
    Curr Cardiol Rep; 2000 May; 2(3):233-43. PubMed ID: 10980898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The utility of levosimendan in the treatment of heart failure.
    Lehtonen L; Põder P
    Ann Med; 2007; 39(1):2-17. PubMed ID: 17364447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure.
    Kivikko M; Lehtonen L
    Curr Pharm Des; 2005; 11(4):435-55. PubMed ID: 15725064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure.
    Cavusoglu Y
    Expert Opin Pharmacother; 2007 Apr; 8(5):665-77. PubMed ID: 17376021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levosimendan: a parenteral calcium-sensitising drug with additional vasodilatory properties.
    Lehtonen LA
    Expert Opin Investig Drugs; 2001 May; 10(5):955-70. PubMed ID: 11322869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levosimendan: dual mechanisms for acute heart failure...and beyond?
    Ng TM; Akhter MW
    Minerva Cardioangiol; 2005 Dec; 53(6):565-84. PubMed ID: 16333239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
    Follath F
    Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levosimendan: a review of its use in the management of acute decompensated heart failure.
    Innes CA; Wagstaff AJ
    Drugs; 2003; 63(23):2651-71. PubMed ID: 14636085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators.
    Slawsky MT; Colucci WS; Gottlieb SS; Greenberg BH; Haeusslein E; Hare J; Hutchins S; Leier CV; LeJemtel TH; Loh E; Nicklas J; Ogilby D; Singh BN; Smith W
    Circulation; 2000 Oct; 102(18):2222-7. PubMed ID: 11056096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Considerations on the efficacy and safety of levosimendan in ischemic heart failure.
    Nieminen MS; Sandell EP
    Ital Heart J; 2003 May; 4 Suppl 2():39S-44S. PubMed ID: 14635369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic treatment of heart failure due to ventricular dysfunction by myocardial stunning: potential role of levosimendan.
    García González MJ; Domínguez Rodríguez A
    Am J Cardiovasc Drugs; 2006; 6(2):69-75. PubMed ID: 16555860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
    Cleland JG; Nikitin N; McGowan J
    Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):9-19. PubMed ID: 15038409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levosimendan: a new era for inodilator therapy for heart failure?
    Cleland JG; McGowan J
    Curr Opin Cardiol; 2002 May; 17(3):257-65. PubMed ID: 12015475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial.
    Cleland JG; Takala A; Apajasalo M; Zethraeus N; Kobelt G
    Eur J Heart Fail; 2003 Jan; 5(1):101-8. PubMed ID: 12559222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levosimendan: a unique approach to the treatment of heart failure.
    Nawarskas JJ; Anderson JR
    Heart Dis; 2002; 4(4):265-71. PubMed ID: 12147186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levosimendan: beyond its simple inotropic effect in heart failure.
    Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
    Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Levosimendan in cardiology and intensive care medicine].
    Delle Karth G; Heinz G
    Wien Klin Wochenschr; 2004 Jan; 116(1-2):6-14. PubMed ID: 15030117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levosimendan, a new calcium-sensitizing inotrope for heart failure.
    Ng TM
    Pharmacotherapy; 2004 Oct; 24(10):1366-84. PubMed ID: 15628834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological mechanisms contributing to the clinical efficacy of levosimendan.
    Papp Z; Csapó K; Pollesello P; Haikala H; Edes I
    Cardiovasc Drug Rev; 2005; 23(1):71-98. PubMed ID: 15867949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.